2025 Spring Clinical
REGISTRATION IS NOW OPEN!
Join us for our Spring Clinical Conference, happening at Creighton University on February 15, 2025!
Stop Overdose Deaths Arizona
SODAz, or Stop Overdose Deaths Arizona, is a partnership of AzPA and the Maricopa County Department of Public Health. Our goal is to increase accessibility of nasal naloxone, reduce deaths by educating the public, and diminish the stigma's related to substance use disorder.
AzPA Legacy Intern Application
An AzPA Legacy Intern is a student member of the AzPA Mentor Connection Program who hopes to stay in Arizona after graduating from an Arizona college of pharmacy in 2026.
Due: Noon on Monday, December 2!
2025 Annual Convention
JUNE 12-15, 2025 | Tucson
Save the date for our Annual Convention! We'll be at the Westin La Paloma in Tucson! Can't wait to see you there...
Refresh Your AzPA Profile!
When was the last time you checked your AzPA profile? Things change all the time - cell numbers, emails, etc. Take a minute and log in so we can get in touch with you!
Login HereAzPA Pharmacy Flash
- Medicare rules may reduce prescription steeringWeill Cornell Medicine researchers found that pharmacy benefit managers in integrated health care conglomerates, including CVS, UnitedHealth Group, Cigna and Humana, have a lower market share in Medicare than national estimates suggest.
- FDA grants ALG-801 orphan drug designation for treatment of pulmonary arterial hypertensionThe FDA has granted an orphan drug designation to ALG-801 for treating pulmonary arterial hypertension, a rare and life-threatening condition. ALG-801, a novel next-generation ActRII/IIB hybrid ligand trap, has demonstrated superior efficacy and improved safety in preclinical and clinical phase 1 studies.
- Glucarpidase boosts recovery from methotrexate-induced acute kidney injuryResearchers at Brigham and Women's Hospital have found that glucarpidase significantly improves kidney recovery in patients with methotrexate-induced nephrotoxicity. The study, which analyzed data from over 700 patients across 28 U.S. cancer centers, is the first comprehensive study to include a control group and adjust for confounders.